How should cold‑induced urticaria be treated and prevented?

Cold-Induced Urticaria: Treatment and Prevention

Start with a standard-dose second-generation H1-antihistamine (cetirizine, desloratadine, fexofenadine, levocetirizine, or loratadine) taken once daily, and if inadequate control is achieved after 2-4 weeks, increase the dose up to 4-fold the standard dose. 1

First-Line Treatment: Antihistamines

Offer patients a choice of at least two different non-sedating H1-antihistamines because individual responses and tolerance vary significantly 1. The seven licensed options include:

• Once-daily agents: Cetirizine, desloratadine, fexofenadine, levocetirizine, loratadine, mizolastine
• Three-times-daily: Acrivastine (short half-life)

Dose Escalation Strategy

If symptoms persist after 2-4 weeks on standard dosing, increase the antihistamine dose up to 4-fold above the manufacturer's licensed recommendation 1. This updosing approach is common practice when potential benefits outweigh risks. Cetirizine and loratadine show enhanced mast-cell stabilizing effects at higher doses 1.

Time medication to ensure peak drug levels coincide with anticipated cold exposure 1.

Special Considerations for Antihistamine Selection

• Cetirizine: Shortest time to maximum concentration—advantageous when rapid availability is critical; may be sedating at higher doses 1
• Desloratadine: Longest elimination half-life (27 hours); discontinue 6 days before skin testing 1
• Mizolastine: Contraindicated in cardiac disease, QT prolongation, and with CYP450 inhibitors 1

Second-Line Treatment: Omalizumab

If antihistamines fail at up to 4-fold dosing, advance to omalizumab 300 mg subcutaneously every 4 weeks 2. This represents the streamlined 2022 guideline approach, moving omalizumab to second-line therapy.

Omalizumab Optimization

• Allow up to 6 months for full response 2
• If insufficient response, updose by shortening intervals and/or increasing dose—maximum recommended is 600 mg every 14 days 2
• Higher doses particularly benefit patients with elevated body mass index 2
• Anecdotal evidence shows resolution of cold urticaria with omalizumab 1

Third-Line Treatment: Cyclosporine

For patients unresponsive to high-dose omalizumab, consider cyclosporine 4 mg/kg daily 1. Approximately two-thirds of patients with severe autoimmune urticaria respond, though only 25% maintain improvement long-term 1.

Monitor blood pressure and renal function (BUN, creatinine) every 6 weeks due to risks of hypertension, renal failure, hirsutism, and gum hypertrophy 2.

Prevention Strategies

Trigger Avoidance

Counsel patients to avoid cold exposure comprehensively:

• Cold water immersion (swimming, water sports)
• Cold air exposure after hot showers
• Cold food/beverage ingestion (increases anaphylaxis risk) 3
• Cold antiseptic solutions during procedures 4

Emergency Preparedness

Prescribe an epinephrine auto-injector for patients at risk of anaphylaxis 5, 6, 7. Risk factors include:

• Male sex
• Autoimmune comorbidities
• Older age at onset
• History of systemic reactions
• Triggers involving cold food/beverage ingestion 3

Emergency kit should contain: epinephrine auto-injector, oral antihistamines, and corticosteroids 7.

Dosing for Emergency Kit

• Adults/adolescents >12 years: 300 µg epinephrine auto-injector
• Children 15-30 kg: 150 µg epinephrine auto-injector
• Repeat dose if no significant relief after first administration 1

Perioperative Management

For patients requiring surgery, particularly with cold exposure risk:

Preoperative preparation (5 days before):

• High-dose second-generation H1-antihistamine 8
• Continue through immediate perioperative period
• Add short-course corticosteroids 4, 8

Intraoperative precautions:

• Limit systemic cooling (e.g., 32°C minimum on cardiopulmonary bypass) 8
• Warm all IV fluids and antiseptic solutions 4
• Active warming at all other times 8

Common Pitfalls

• Don't abandon antihistamines prematurely—allow 2-4 weeks at each dose level before escalating
• Don't restrict swimming entirely—authorize under strict conditions (gradual immersion, supervision, warm water) but contraindicate other water sports 5
• Don't overlook occupational cold exposure—68.4% of experts contraindicate this 5
• Don't use H2-antihistamines as monotherapy—they may provide marginal additional benefit to H1-antihistamines but are more useful for accompanying dyspepsia 1

Step-Down Protocol

Once complete disease control is achieved (UCT score ≥16), consider stepping down treatment 2:

• Maintain complete control for at least 3 consecutive months before reducing dose
• Reduce by no more than 1 tablet per month
• If breakthrough symptoms occur, return to last effective dose 2

Prognosis

The prognosis for eventual recovery from physical urticarias is excellent, though some cases may be especially persistent 1. Median disease duration is approximately 18 months in pediatric cohorts, with 30.5% achieving resolution 3. History of anaphylaxis and comorbid atopic disease significantly reduce likelihood of remission 3.